Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
暂无分享,去创建一个
John W. Park | D. Drummond | C. Noble | D. Kirpotin | K. Hong | Daryl C Drummond | Keelung Hong | John W Park | Dmitri B Kirpotin | Charles O Noble | Zexiong Guo | Zexiong Guo
[1] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[2] D. Baccanari,et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] M. Newman,et al. The effect of vincristine–polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity , 1996, Cancer Chemotherapy and Pharmacology.
[4] A. Kawai,et al. Kinetic Studies of the Hydrolysis and Lactonization of Camptothecin and Its Derivatives, CPT-11 and SN-38, in Aqueous Solution , 1994 .
[5] S. Guichard,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0364 CPT-11 converting carboxylesterase and topoisomerase I , 2022 .
[6] L. Mayer,et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. , 2001, The Journal of pharmacology and experimental therapeutics.
[7] H. Kuga,et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.
[8] J. Supko,et al. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Imran Ahmad,et al. Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.
[10] M. Woodle,et al. Pharmacokinetics and anti‐tumor activity of vincristine encapsulated in sterically stabilized liposomes , 1995, International journal of cancer.
[11] M. Bally,et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. , 1995, British Journal of Cancer.
[12] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[13] M. Bally,et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.
[14] U. Vanhoefer,et al. Irinotecan in the treatment of colorectal cancer: clinical overview. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Fisher Rs. Sucralfate: a review of drug tolerance and safety. , 1981 .
[16] S. Hirota,et al. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. , 1998, Cancer letters.
[17] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[18] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] L. Huang,et al. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.
[20] Wooin Lee,et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. , 2005, The oncologist.
[21] H. McLeod,et al. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] T. Burke,et al. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[23] R. Geran,et al. PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS , 1972 .
[24] C. Benz,et al. Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes , 2005, Clinical Cancer Research.
[25] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[26] M. Berger,et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.
[27] G. Giaccone,et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. , 1998, British Journal of Cancer.
[28] D. Deamer,et al. Catecholamine uptake and concentration by liposomes maintaining p/ gradients. , 1976, Biochimica et biophysica acta.
[29] Corrie Lynn Messerer,et al. Liposomal Irinotecan , 2004, Clinical Cancer Research.
[30] M. Bally,et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.
[31] J Verweij,et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] D. Carbonaro,et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. , 2005, Anticancer research.
[33] P. Uster,et al. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] R. Fisher. Sucralfate: a review of drug tolerance and safety. , 1981, Journal of clinical gastroenterology.
[35] G. R. Bartlett. Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.
[36] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[37] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[38] J H Senior,et al. Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.
[39] S. Hirota,et al. Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38 , 1999, Japanese journal of cancer research : Gann.